Pancreas transplantation

EQS-News: AATec Medical GmbH: AATec Medical Announces its Launch with EUR 2.7 million in Seed Financing to Unlock the Therapeutic Potential of Alpha-1 Antitrypsin

Retrieved on: 
Monday, July 17, 2023
Inhalation, Asthma, Viral, Research, Lung, Trial of the century, Teaching hospital, Plasma, EUR, Genetic disorder, Pancreas transplantation, AAT, Cytokine, Inflammation, Pharmaceutical industry

The funds will be used to scale up AATec’s technology, expand the team and prepare for clinical studies expected to start in 2024.

Key Points: 
  • The funds will be used to scale up AATec’s technology, expand the team and prepare for clinical studies expected to start in 2024.
  • The first product candidate, ATL-105, is a novel AAT formulation for inhalation to treat emerging inflammatory diseases of the lung and respiratory virus infections.
  • Alpha-1 antitrypsin (AAT) is a human serine protease inhibitor (SERPIN) essential for tissue protection from damage by proteases.
  • AAT has immunomodulatory functions and provides broad anti-inflammatory and antiviral therapeutic effects through binding to pro-inflammatory cytokines and targeted protease inhibition.

Endsulin Announces Passing of Founder Hans Sollinger, MD, PhD

Retrieved on: 
Friday, May 19, 2023
Insulin, University, Diabetes, T1D, American Board of Internal Medicine, Pancreas, Pancreas transplantation, Transplant surgeon, Research, Patient, Pioneer Award, Recurrence, Immunosuppression, Society, T1DM, Pharmaceutical industry

MADISON, Wis., May 19, 2023 /PRNewswire/ -- Endsulin announced today that Founder and Chief Scientific Officer Hans Sollinger, M.D., Ph.D., passed away peacefully on May 15, 2023, after a recurrence of a previous illness.

Key Points: 
  • MADISON, Wis., May 19, 2023 /PRNewswire/ -- Endsulin announced today that Founder and Chief Scientific Officer Hans Sollinger, M.D., Ph.D., passed away peacefully on May 15, 2023, after a recurrence of a previous illness.
  • In 2016, after 20 years of research, he founded Endsulin, an early-stage biotech company based on Dr. Sollinger's proprietary technology.
  • Endsulin is developing a single dose, liver-directed gene therapy that enables liver cells to produce and regulate insulin, mimicking the function of the pancreas.
  • "The passing of Hans is a profound loss," said Endsulin's Chairman of the Board and CEO, Thomas Dee.

CareDx Joins Forces with National Kidney Foundation and Honor the Gift Coalition to Host Immuno Bill Webinar for Kidney Transplant Patients

Retrieved on: 
Wednesday, October 26, 2022
General Health, Other Health, Health, Telemedicine, Virtual Medicine, Health Insurance, Pancreas transplantation, Caregiver, Bill, Transplant, SEC, Dialysis, Capitol Hill, Transplant surgeon, Policy, Organization, Annual report, Volunteering, Part, Patient, Society, Donate Life America, NKF, Nasdaq, Precision medicine, Medicare, MD, Legislation, National Kidney Foundation, CEO, Gift, Coalition, Heart, 21st Century Cures Act, Pharmaceutical industry, Health insurance, Dentistry, Kidney

Often referred to as the "Immuno Bill", the Bill becomes effective January 1, 2023.

Key Points: 
  • Often referred to as the "Immuno Bill", the Bill becomes effective January 1, 2023.
  • "At CareDx, transplant patients are at the heart of everything we do, and it gives us great pride to have led the formation of the Honor the Gift Coalition in the successful passage of the Immuno Bill," said Reg Seeto, CEO and President of CareDx.
  • NKF is proud to partner with CareDx to host this educational webinar to ensure that all kidney transplant patients and their families understand how to navigate the new Immuno Bill requirements," stated Kevin Longino, transplant recipient and CEO of the National Kidney Foundation.
  • In March 2019, driven by its dedication to serving transplant patients and caregivers, CareDx launched the Honor the Gift Coalition a national patient-centered campaign focused on rallying the kidney community for the passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020 (Immuno Bill).

CareDx Leads Transplant Innovation with AiKidney, an AI Clinical Decision Support Tool for Predicting Allograft Rejection Risk

Retrieved on: 
Thursday, June 2, 2022
Medical Devices, Health, Surgery, Pharmaceutical, Cardiology, Biotechnology, Online, Biomarker, Prognosis, Caregiver, Congress, Precision medicine, Kidney transplantation, PMID, Doctor of Philosophy, Survival, Dave's Picks Volume 37, Validation, Dean Hart, Medical director, Kidney failure, Population, Pancreas transplantation, FC, Cardiac allograft vasculopathy, ATC, Artificial intelligence, DOI, Veni, vidi, vici, CLIA, CEO, Partnership, ET, Solution, Immunosuppression, Illusion of validity, Annual report, University, Physician, Long-term care, CAV, Patient, DNA, Gene expression, SEC, University of Utah, Nasdaq, Utility, Risk, Kidney International, Y Touring Theatre Company, Death, Dentistry, Medical device, Pharmaceutical industry, Entertainment, Silviculture, Sex industry, Transplant, Kidney, MD, Medicine

This follows CareDxs recently announced plans to add an artificial intelligence (AI) prognostic for cardiac allograft vasculopathy (CAV).

Key Points: 
  • This follows CareDxs recently announced plans to add an artificial intelligence (AI) prognostic for cardiac allograft vasculopathy (CAV).
  • AiKidney can be used for informing clinical management decisions and to help clinicians predict the long-term impact of treatments.
  • This ongoing partnership is yielding positive results and it is exciting to see AiKidney coming to fruition in the clinic.
  • AiKidney supports this assessment by providing information about a patients risk of allograft rejection and expected long-term graft survival.

CareDx Innovation Showcased in Record-Breaking Number of Scientific Abstracts with Over 50 Presented at 2022 Transplant Congress

Retrieved on: 
Wednesday, June 1, 2022
Biotechnology, Surgery, Health, Pharmaceutical, Cardiology, Use, Pancreas transplantation, Caregiver, Congress, Precision medicine, Time, ATC, Gene expression profiling, Heart transplantation, Detection, Validation, Annual report, World Creativity and Innovation Day, 2021 Essex County Council election, Answer, Patient, COVID-19, SEC, Male, Population, Leadership, Transplant, Dentistry, Sex industry, Female

Development and Validation of an Integrative DD-CFDNA System to Predict Allograft Rejection: A Population Based Study

Key Points: 
  • Development and Validation of an Integrative DD-CFDNA System to Predict Allograft Rejection: A Population Based Study
    Can dd-cf DNA Eliminate Unnecessary Biopsies?
  • Note: The product theaters, symposium, and innovation day are not part of the official ATC educational program, and the sessions and content are not endorsed by ATC.
  • CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients.
  • CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

American Kidney Fund Survey Underscores Need to Expand Testing for Chronic Kidney Disease and Increase Awareness of Rare Kidney Diseases

Retrieved on: 
Thursday, April 7, 2022
Risk, Trustee, Therapy, BMP, American Kidney Fund, Kidney failure, Polycystic kidney disease, Candid (organization), CMP, CEO, Cyst, GLOBE, AKF, Nephrology, Education, Vertex Pharmaceuticals, University, Disease, Diagnosis, Biopsy, Genetic testing, Kidney disease, Hypertension, Charity Navigator, University of Michigan, Surgeon, Platinum, Chronic kidney disease, Glomerular filtration rate, Board, Board of directors, Health, Diabetes, Genetic disorder, Disease management, Awareness, Conditional sentence, Patient, PKD, HIV disease progression rates, Pancreas transplantation, MPH, Type 2 diabetes, CKD, Physician, EGFR, Practitioner, Pharmaceutical industry, Dentistry, Medical imaging, Kidney, Natera, MD

In AKFs survey, health care providers said they estimated 15% of their patients have kidney disease with no known cause.

Key Points: 
  • In AKFs survey, health care providers said they estimated 15% of their patients have kidney disease with no known cause.
  • AKF is advocating for federal legislation that would improve access to genetic counselors and shine a spotlight on rare kidney disease.
  • The American Kidney Fund (AKF) fights kidney disease on all fronts as the nations leading kidney nonprofit.
  • All survey respondents had treated at least 20 people with chronic kidney disease in the prior month.

CareDx to Host Symposium at CEoT Featuring the Latest Multimodality Innovations in Kidney and Lung Transplant Surveillance

Retrieved on: 
Wednesday, April 6, 2022
University of Maryland Medical Center, NYU Langone Health, Multi-Modal Logistics Parks in India, DO, Critical Care Medicine (journal), DNA, Nephrology, Loyola University, LSU Health Sciences Center New Orleans, Patient, Caregiver, Pancreas transplantation, Vaccination, SEC, Decision-making, MPH, Associate, Precision medicine, Severe acute respiratory syndrome coronavirus 2, CEO, Maryland School, Lung transplantation, Society, FASN, Nasdaq, University of Maryland School of Medicine, GLOBE, Associate professor, Solution, University of Texas at Austin, SAN, Annual report, Division, University, Infection, Dentistry, Vaccine, Pharmaceutical industry, Medicine, Kidney, MD, Transplant, Symposium

The latest advancements in multimodality surveillance using CareDxs AlloSure donor-derived cell-free DNA (dd-cfDNA), AlloMap gene-expression profiling, and other new emerging modalities for assessing allograft injury, rejection, and infection in kidney and lung transplantation will be presented.

Key Points: 
  • The latest advancements in multimodality surveillance using CareDxs AlloSure donor-derived cell-free DNA (dd-cfDNA), AlloMap gene-expression profiling, and other new emerging modalities for assessing allograft injury, rejection, and infection in kidney and lung transplantation will be presented.
  • The study showed that the stability of dd-cfDNA after SARS-CoV-2 vaccine booster administration reinforces the vaccines safety profile in kidney transplant patients.
  • This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDxs hosting of a symposium featuring the latest multimodality innovations in kidney and lung transplant surveillance at CEoT (the Symposium).
  • CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

Humacyte Announces Publication of In Vivo Data on Biovascular Pancreas Transplantation for the Treatment of Type 1 Diabetes

Retrieved on: 
Wednesday, August 11, 2021
Constellation, Cell Transplantation, Diabetes, Patient, Prospectus, Proxy, Technology, Duke University School of Medicine, Tissue, Sale, PIPE, BVP, Failure, Acquisition, GLOBE, Form, Journal, HAV, Company, Animal, Forward-looking statement, AHAC, Manuscript, Survival, Nasdaq, Investment, Securities Act of 1933, Transplant, Combined, Intention, Journal of Tissue Engineering, Pancreas transplantation, Health, Review, Disease, Person, Injury, Insulin, Terminology, Method, Pediatrics, Quality of life, Pancreas, Injection, FACS, Cell death, Medicine, Moyamoya disease, COVID-19, Tissue engineering, Vibration, SEC, RATS, Pharmaceutical industry, Security (finance)

The global market for the treatment of type 1 diabetes is estimated to be approximately $60 billion per year.

Key Points: 
  • The global market for the treatment of type 1 diabetes is estimated to be approximately $60 billion per year.
  • Humacyte is developing the biovascular pancreas (BVP), leveraging its human acellular vessels (HAVs) as a vascular scaffold, to be implanted in an outpatient procedure.
  • We are excited to share this data that supports the application of a biovascular pancreas to provide an effective method for the treatment of type 1 diabetes, said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte.
  • Islet cell transplantation can be an important long-term treatment option for people with type 1 diabetes who no longer make their own insulin.

Humacyte Presents In Vivo Data on Biovascular Pancreas Transplantation for Type 1 Diabetes Treatment

Retrieved on: 
Tuesday, June 8, 2021
Medical specialties, Clinical medicine, Medicine, Diabetes, Organ transplantation, Pancreas transplantation, Insulin, Pancreatic islets, Type 1 diabetes, Pancreas, Islet cell transplantation, Edmonton protocol

The data show that pancreatic islet cells embedded in the outer matrix of an acellular vessel can create a biovascular pancreas transplant.

Key Points: 
  • The data show that pancreatic islet cells embedded in the outer matrix of an acellular vessel can create a biovascular pancreas transplant.
  • These data demonstrate the potential to engineer a biovascular pancreas based on our HAV platform technology, that may effectively deliver islet cells that can produce insulin for people with Type 1 diabetes.
  • Type 1 diabetics no longer make their own insulin, and currently face limited curative treatment options including pancreas transplant, which is a morbid procedure.
  • Without transplantation, Type 1 diabetics are committed to life-long insulin use, said Jeffrey Lawson, M.D., Ph.D., Chief Surgical Officer of Humacyte.

Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research Collaboration on Tonix’s Third Generation anti-CD40-Ligand Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Kidney Transplant Rejection

Retrieved on: 
Tuesday, January 5, 2021
Medical specialties, Clinical medicine, Organ transplantation, Medicine, Kidney transplantation, Transplant rejection, Heart transplantation, CD40, Pancreas transplantation, Liver transplantation

Transplant organ rejection occurs when the immune system of the organ recipient attacks the new organ as if it was an infection or tumor.

Key Points: 
  • Transplant organ rejection occurs when the immune system of the organ recipient attacks the new organ as if it was an infection or tumor.
  • The new collaboration will focus on kidney transplantation, while an earlier collaboration with MGH is focused on heart transplantation.
  • The goal of the collaboration is to advance TNX-1500 as a potential first-in-class therapeutic to prevent and treat kidney transplant rejection.
  • Second generation anti-CD40- ligand mAbs had dramatically reduced binding to FcRII, but had other issues, including decreased efficacy5-7.